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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2016, TaiwanBackground: We aimed to study the changes of serum N-terminal pro-brain natriuretic to pep-
tide (NT-proBNP) levels after asphyxia-induced myocardial injury in children and explore the
relationship between serum NT-proBNP levels and neonatal asphyxia.
Methods: One hundred and six cases of neonatal asphyxia were randomly selected for the
study, including 46 severe cases with myocardial injury and 60 mild cases with no cardiac
injury. Sixty-three healthy newborns were selected as the control group. The serum NT-
proBNP level was detected using electrochemiluminescence. Creatine kinase MB (CK-MB)
and serum sodium and calcium were measured simultaneously.
Results: The serum NT-proBNP level in the myocardial injury group was significantly higher
than that of the noncardiac injury and control groups (p < 0.01). Asphyxia serum NT-proBNP
and cardiac enzymes were significantly correlated. The median value of neonatal NT-proBNP
was 1491 pg/mL at postnatal Day 3 (P3) and 1077 pg/mL at postnatal Day 14 (P14). The cutoff
value for children with myocardial injury was 3612.5 pg/mL; the area under the receiver oper-
ating characteristic curve was 0.80 (p < 0.001), with a sensitivity of 83.3%, a specificity of
80.5%, a positive predictive value of 82.8%, and a negative predictive value of 79.4%. After
treatment, the serum NT-proBNP level in children with myocardial damage showed a signifi-
cant decrease.
Conclusion: The serum NT-proBNP level can reflect myocardial injury in neonates with
asphyxia and can guide its diagnosis.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.Rd., Wuchang District, Wuhan, Hubei 430071, China
ail.com (R. Zhu).
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134 R. Zhu, Z. Nie1. Introduction
Neonatal asphyxia is a common pediatric disease with an
incidence of 5e10% in China.1 Asphyxia causes hypoxia and
leads to multiple organ damage, of which heart damage is
the most common. Reports show that the occurrence of
myocardial damage in neonatal asphyxia was 28e65%2 or
even up to 73%.3 However, the diagnosis of hypo-
xiceischemic myocardial damage has been difficult
because of the lack of sensitive laboratory tests for early
diagnosis and the absence of standard diagnostic criteria.
Creatine kinase MB (CK-MB), which exists mainly in the
cytoplasm of myocardial cells, is currently accepted as an
indicator and has high sensitivity and specificity for the
diagnosis of myocardial injury.4 The serum CK-MB level was
found to be closely related to the time after myocardial
injury; a normal CK-MB level in the first detection does not
completely eliminate the possibility of myocardial injury.
CK-MB is also present in the bones and brain in small
amounts.5e7 As a result, we aimed to search for an addi-
tional laboratory marker for an early diagnosis of myocar-
dial injury.
Brain natriuretic peptide, or B-type natriuretic peptide
(BNP), is a heart peptide hormone. When the tension of a
blood vessel increases or its volume is overloaded, pre-
proBNP mRNA is rapidly transcribed in the myocardial cells
of the ventricles. PreproBNP is then synthesized and pro-
cessed to produce a signaling peptide and proBNP. The
proBNP is then catalyzed to generate N-terminal (NT-
proBNP) and BNP, which are released into the blood.
BNP/NT-proBNP has attracted clinical attention as a
marker of cardiac function. In recent years, studies in
adults have demonstrated that BNP/NT-proBNP is an indi-
cator of left ventricular dysfunction.8,9 In heart failure,
plasma BNP/NT-proBNP levels increase dramatically ac-
cording to heart failure severity.10e12 In addition, the BNP/
NT-proBNP levels are the strongest independent prognostic
indicator for death or cardiovascular incidents in patients
with heart failure after discharge.13,14 In the study of
myocardial infarction, an increase in the BNP/NT-proBNP
level appears to be correlated with the timing and extent
of myocardial infarction.15 Therefore, the BNP/NT-proBNP
level is useful for the detection of chronic ventricular
dysfunction in adults and congestive heart failure in pa-
tients with breathing difficulty; the BNP/NT-proBNP level
allows for the diagnosis of subclinical asymptomatic pa-
tients with left ventricular abnormalities.
However, there are relatively few studies regarding
BNP/NT-proBNP in the newborn. NT-proBNP does not pass
the blood-placenta barrier; thus, any changes in the baby’s
body are autonomous. Myocardial ischemia and energy
metabolism dysfunction lead to irreversible damage and
even necrosis. Furthermore, during recovery, blood reper-
fusion can cause further damage to myocardial cells.
Myocardial injury often occurs simultaneously with
elevated ventricular tension and a compensatory increase
in cardiac output. Particularly, in the event of heart failure,
the ventricle is stretched by atrial and ventricular dilata-
tion. At the same time, pulmonary vasodilation stimulates
pulmonary and cardiac nerve receptors, regulating the
release of BNP. The increase in the vascular BNP/NT-proBNPconcentration leads to an increase of the ventricular vol-
ume. The elevated blood vessel pressure further induces
the synthesis and secretion of BNP.16,17 Goetze et al18
showed that myocardial hypoxia affects ventricular BNP
gene expression and increases the plasma BNP/NT-proBNP
concentration, suggesting that the elevated plasma BNP/
NT-proBNP levels in the acute phase of myocardial injury




According to the visit order, every other case was selected
from patients who were admitted to our hospital from
December 2012 to December 2013 in accordance with the
hospital’s neonatal asphyxia standards. A total of 106 cases
of neonates <3 days old were selected. We obtained
informed consent from the parents or legal guardians of the
patients, and this study was approved by the Zhongnan
Hospital of Wuhan University Ethics Committee.
According to the Apgar scoring method,19 we performed
1-minute and 5-minute scores for neonatal asphyxia. When
the 5-minute score was <7, we scored the patient every 5
minutes until 20 minutes had passed. Patients with a 1-
minute Apgar score of 0e3 were categorized as having se-
vere asphyxia, and patients with a score of 4e7 were
categorized as having mild asphyxia according to the clin-
ical presentations of myocardial damage in neonatal
asphyxia20: (1) history of asphyxia and perinatal hypoxia;
(2) clinical manifestations: i) low, blunt heart sound and
tachycardia; ii) poor circulation, demonstrated by a pale
complexion, finger cyanosis, or capillary refill time over 3
seconds; iii) heart failure; iv) severe arrhythmias; and v)
cardiac arrest; (3) electrocardiogram (ECG) ST-T changes
that last for > 2e3 days; and (4) an increase in serum CK-MB
or troponin T. The diagnosis of myocardial injury must
satisfy the following: (1) history of asphyxia; (2) low, blunt
heart sound and poor circulation; (3) ECG abnormalities;
and (4) enzyme abnormalities, as listed above in detail.
In the 106 asphyxia cases, 46 met the diagnostic criteria
of myocardial injury.21 The control group of neonates was
admitted in the same period; these neonates did not have
asphyxia or neonatal cardiovascular disease. Instead, they
had a mild upper respiratory tract infection, omphalitis, or
mild diarrhea. Neonates with water and electrolyte balance
disorders and kidney dysfunction were excluded from the
control group. Gestational age, birth weight, sex, or mode
of delivery was not significantly different among the three
groups. See Table 1 for the demographic data of all of the
cases selected in our study and Table 2 for the clinical
manifestations of the patients.
2.2. Methods
We first established a neonatal datasheet that included
age, sex, admission time, mode of delivery, birth weight,
gestational age, history of fetal distress, and Apgar score.
Then, routine ECG and chest X-ray examinations were
Table 1 Demographic data of patients and controls.
Severe asphyxia
group (n Z 44)
Mild asphyxia




Sex Male 22 38 39 0.405
Female 22 24 24 0.405
Gestational age (wk) 32w35 16 26 14 0.059
w37 18 17 27 0.160
w40 9 17 20 0.434
w40 1 2 2 0.952
Birth weight (g) 1000w1500 11 18 10 0.205
1501w2500 21 31 28 0.823
2501w4000 10 10 20 0.120
w4000 2 3 5 0.691
Mode of delivery Natural birth 20 18 17 0.101
Cesarean section 24 44 46 0.101
Clinical manifestation NRDS 52 30 URI 36
HIE 13 1 Omphalitis 11
NEC 14 2 Mild diarrhea 17
Anemia 38 20
Myocardial injury 42 4
Jaundice 32 10
HIE Z hypoxic-ischemic encephalopathy; NEC Z Necrotizing enterocolitis; NRDS Z Neonatal respiratory distress syndrome;
URI Z Urinary tract infection.
NT-BNP in Neonatal Myocardial Injury 135performed. A 2 mL blood sample was drawn from the
femoral vein of children within 2 hours of admission to the
hospital and again on Day 14. The blood sample was mixed
with ethylene diamine tetra-acetic acid and centrifuged for
15 minutes at 2500 rpm/min at room temperature. The
serum was collected for the detection of CK-MB, serum
sodium and calcium, and was stored at 70C. The serum
NT-proBNP level was measured with an electro-
chemiluminescence kit (Roche, Shanghai, China), using the
Elecsys 2010 instrument. The detection sensitivity was
50 pg/mL and the detection range was 5e35,000 pg/mL.
2.3. Statistics
SPSS version 17 software (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Because the NT-proBNP test
results were not normally distributed, we performed a







History of asphyxia and hypoxia 46 100.00
Clinical manifestation 100.00
Low, blunt heart sound 46 100.00
Poor circulation 46 100.00
Heart failure 13 28.26
Severe arrhythmia 12 26.09
Cardiac arrest 2 4.35
ECG abnormalities 46 100.00
Enzyme abnormalities 46 100.00
ECG Z electrocardiogram.using the Student t test. Multiple groups were analyzed
with analysis of variance and were expressed as the
mean  standard deviation. Plasma NT-proBNP and a vari-
ety of factors were examined by rank correlation analysis
and multiple linear regression. The receiver operating
characteristic (ROC) curve was determined by plotting the
cutoff value to further clinical diagnosis.3. Results
We first determined the NT-proBNP level of neonatal chil-
dren of varying asphyxia degrees at different time points
compared with the control group. Within 3 days after birth,
compared with the control group, the serum NT-proBNP
levels of both severe and mild asphyxia groups were
significantly higher than the control group, and the serum
NT-proBNP level of the severe asphyxia group was also
significantly higher than the mild asphyxia group. However,
in the second week after birth, the NT-proBNP level of the
severe asphyxia group was not significantly different from
the mild asphyxia or control groups (Table 3).
We then examined the serum NT-proBNP level of chil-
dren with or without cardiac injury at different time points
compared with the control group. Three days after birth,
the NT-proBNP level of children with cardiac injury was
significantly higher than suffocated children without car-
diac injury and the control group. Suffocated children
without cardiac injury also had higher NT-proBNP levels
than the control group. After treatment at 2 weeks, the
serum NT-proBNP levels of all three groups were not
significantly different from each other (Table 4). Further-
more, the NT-proBNP level in the cardiac injury group was
significantly lower than before treatment (p < 0.05), but
the nonmyocardial injury group and the control group
showed no significant difference (p > 0.05).
Table 3 NT-proBNP level of neonatal children with varying degress of asphyxia.
Groups Severe asphyxia
group (n Z 44)
Mild asphyxia




logNT-proBNP (pg/mL) 3 d 3. 916  0.194*,y 3.173  0.309 2.778  0.495 85.648 <0.001
2 wk 2.987  0.286z 2.854  0.309 2.607  0.554 3.226 >0.05
* Compared with the mild asphyxia group, p < 0.05.
y Compared with the control, p < 0.05.
z Compared with the control, p < 0.05.
Table 4 N-terminal pro-brain natriuretic peptide (NT-proBNP) and creatine kinase MB (CK-MB) levels of suffocated children
with and without myocardial injury.
Groups Myocardial damage
group (n Z 46)
Noncardiac damage




logNT-proBNP (pg/mL) 3 d 3.86  0.262*,y 3.30  0.317 2.78  0.495 72.52 <0.001
2 wk 2.98  0.305z 2.89  0.349 2.61  0.554 3.120 >0.05
CK-MB (units/L) 3 d 175.87  109.520*,y 47.60  8.500 57.38  29.91 26.522 0.001
2 wk 54.00  27.524z 49.26  0.895 47.67  14.974 0.799 0.454
* Compared with the noncardiac damage group, p < 0.05.
y Compared with the control, p < 0.05.
z Compared with the control, p < 0.05.
136 R. Zhu, Z. NieIn the myocardial injury group, the NT-proBNP levels of
children with mild asphyxia and severe asphyxia were
significantly different (T Z 2.578, p Z 0.032) (T: ratio of
the difference between the mean of the severe asphyxia
group and the mean of the mild asphyxia group over the
standard error of the mild asphyxia group). However, the
NT-proBNP levels of children with a 5 minute Apgar score
>7 and  7 did not differ significantly (T Z 1.516,
p Z 0.138).
Because CK-MB is accepted as an indicator for the
diagnosis of myocardial injury, we examined its relationship
with NT-proBNP. The NT-proBNP level is positively corre-
lated with CK-MB in children with myocardial injury
(Spearman correlation, r Z 0.405, p Z 0.007). However,
the NT-proBNP level was negatively correlated with the
serum sodium level (Spearman correlation, r Z 0.342,
pZ 0.025), but was not correlated with the serum calcium
level (p > 0.05).
We also determined the NT-proBNP levels in normal
neonates of the control group. The serum level of NT-
proBNP gradually declines during the first 2 weeks after
birth (Table 5).
At present, there is no uniform standard for the normal
NT-proBNP range. We used an ROC curve to determine the
optimal cutoff value and analyzed the sensitivity, speci-
ficity, and positive and negative predictive values. In our
study, the NT-proBNP level is very high at birth and thenTable 5 Changes in N-terminal pro-brain natriuretic
peptide (NT-proBNP) level after normal birth (pg/mL).




P0-3 63 1491 2373 499.5 8607.3
P14 63 1077 2039 423.04 5597.6rapidly declines. We set the NT-proBNP cutoff value for
neonatal myocardial injury at 3612.5 pg/mL. The area
under the ROC curve is 0.80 (p < 0.001), the sensitivity is
83.3%, the specificity is 80.5%, the positive predictive value
is 82.8%, and the negative predictive value is 79.4%
(Figure 1).Figure 1 Receiver operating characteristic (ROC) curve of
serum N-terminal pro-brain natriuretic peptide (NT-proBNP).
Creatine kinase MB (CK-MB) is divided into two groups at 70
units. Then, the ROC curve is plotted with the N-terminal pro-
brain natriuretic peptide as a test variable and the CK-MB
groups as the state variable. The abscissa is specificity, and
the ordinate axis is the sensitivity.
NT-BNP in Neonatal Myocardial Injury 137To determine the relationship of serum NT-proBNP and
various factors in children with myocardial injury after
neonatal asphyxia, we analyzed perinatal factors, including
the mother’s age, gender of the children, gestation length,
placental function, mode of delivery, fetal distress, birth
weight, Apgar score, and length of hospitalization. After
stepwise regression screening, two factors were eventually
selected in the model, namely, the Apgar score (p < 0.001)
and gestational age (p Z 0.042). Both are negatively
correlated with the serum NT-proBNP level (Table 6). When
the Apgar score is controlled, regression shows that the
serum NT-proBNP level is negatively correlated with
gestational age (B Z 0.239, p Z 0.019) (B is the slope of
the regression line), while the other factors did not show
any correlation. When gestational age is controlled, the NT-
proBNP level shows a negative correlation with the Apgar
score (B Z 0.74, p < 0.001), whereas the other factors
are not correlated with the NT-proBNP level.
4. Discussion
In this study, we examined the serum NT-proBNP levels in
children with neonatal asphyxia. Compared with normal
newborns, the level of NT-proBNP increased significantly in
suffocated children, with an even stronger effect in the
severe asphyxia group. Furthermore, we found that suffo-
cated children with myocardial injury had significantly
higher serum NT-proBNP levels than the noncardiac injury
and control groups. Serum NT-proBNP levels were positively
correlated with cardiac enzymes, suggesting that the
elevated plasma BNP/NT-proBNP levels in the acute phase
of myocardial injury in children were associated with acute
phase-localized myocardial ischemic injury. In the event of
hypoxia, myocardial cells are damaged, allowing myocar-
dial enzymes to escape, leading to elevated serum enzyme
activity.22 Based on clinical studies of myocardial injury and
deficiency, Gu23 suggested that the diagnosis sensitivity was
w50% and specificity wasw75% when the diagnosis is based
on experience. However, when the diagnosis is combined
with serum NT-proBNP detection, the diagnosis sensitivity
can be increased to 90% and the specificity to 87%.24 In our












Apgar score 1681.041 0.803
Gestational age 1311.323 0.227
Gender 244.656 0.027
Mode of delivery 50.893 0.031




Fetal distress 287.147 0.031
Mother’s age 353.120 0.106neonates with myocardial injury was set at 3612.5 pg/mL,
the diagnosis sensitivity was 83.3%, the specificity was
80.5%, the positive predictive value was 82.8%, and the
negative predictive value was 79.4%.
The serum NT-proBNP level in neonates with myocar-
dial injury is associated with various factors. The serum
NT-proBNP level is negatively correlated with gestational
age. In addition, it is negatively correlated with Apgar
scores, indicating that more severe asphyxia leads to
higher serum NT-proBNP levels and more severe myocar-
dial damage. Surprisingly, the NT-proBNP levels of children
with a 5 minute Apgar score >7 and  7 did not differ
significantly (F Z 1.516, p Z 0.138) (The F ratio is the
ratio of two mean square values), suggesting that the
serum NT-proBNP level is independent of the duration of
suffocation, which might be a result of the limited number
of cases in our study. The serum NT-proBNP level has a
negative correlation with serum sodium, suggesting that
hyponatremia may occur with increasing NT-proBNP
levels. NT-proBNP can promote the excretion of sodium
and water, resulting in hypovolemic hyponatremia25,26 and
decreased myocardial blood flow, which aggravates
ischemic injury after suffocation and creates a vicious
feedback loop. Therefore, the simultaneous detection of
serum sodium in suffocated children and timely correction
of hyponatremia should help in the treatment and pre-
vention of myocardial injury. In addition, fetal distress can
cause hypoxia and further lead to fetal myocardial injury.
In general, a more severe injury requires longer hospital-
ization. Nuntnarumit et al27 found that the NT-proBNP
level is closely correlated with fetus weight at birth and
that the NT-proBNP level on neonatal Day 1 has a weak
negative correlation with gestational age. However, we
found that the NT-proBNP level was not correlated with
age of the mother at pregnancy, gender of the child,
serum calcium, placental function, mode of delivery, fetal
distress, birth weight, or length of hospitalization. Inter-
estingly, although fetal distress is closely related to the
Apgar score, we were unable to find a negative correlation
between fetal distress and the NT-proBNP level. This
might be because of the limited number of cases with




p t 95.0% Confidence interval
for B
Lower bound Upper bound
6818.488 0.077 1.786 1341.949 2569.657
152.947 0.000 10.991 1984.275 1377.808
167.093 0.042 2.078 13.153 681.400
633.008 0.700 0.386 1499.655 1010.000
199.665 0.799 0.255 344.962 446.748
0.650 0.417 0.102 0.759 1.819
32.397 0.229 1.211 103.454 25.000
658.807 0.664 0.436 1593.296 1019.000
225.169 0.120 1.568 799.538 93.299
138 R. Zhu, Z. NieIn general, mild asphyxia does not lead to myocardial
injury. Nevertheless, there are two exceptions in our study.
In one case, the patient’s heart structure was normal.
However, both parents of the patient had many years of
drug abuse and did not stop drug use during pregnancy,
which may have caused chronic hypoxia for the fetus and,
as a result, myocardial injury could have occurred under
mild asphyxia. In the other case, the patient had a ven-
tricular septal defect. Therefore, with increased resistance
in pulmonary circulation, even mild asphyxia can cause
myocardial damage.
After treatment, the serum NT-proBNP level of children
with myocardial injury decreased significantly at 2 weeks,
approaching the levels observed in the control group.
However, the nonmyocardial injury and control groups
showed no significant difference. These results indicate
that serum NT-proBNP is a marker for heart function
improvement.
It has been reported that the NT-proBNP level reaches a
maximum in the first 3 days after birth, gradually de-
creases, and then stabilizes at a certain level.28e31 Our
study examined the NT-proBNP level at 3 days and 2 weeks
after birth and confirmed that it maintains a high level right
after birth and gradually declines.
Early clinical manifestations of neonatal myocardial
injury after asphyxia are not obvious and often rely on
laboratory tests for its diagnosis. Our study demonstrated
that the serum NT-proBNP level is a useful marker for
neonatal myocardial injury after asphyxia and can be used
to determine the severity of the injury and guide treat-
ment. However, the normal range for the neonatal NT-
proBNP level remains to be determined. In addition, some
of the asphyxia patients in our study were preterm babies
with low birth weights. Complications, such as Patent
Ductus Arteriosus (PDA) and respiratory distress syndrome
(RDS), may increase the cardiac load. These limitations
require further examination with an expanded sample size.
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